The FDA has dropped its complaint against fitness tracker company Whoop over its blood pressure monitoring feature, reversing its earlier demand that the tool be disabled.
The reversal marks a significant shift in the agency's regulatory stance toward Whoop's wearable device. The FDA initially took issue with the blood pressure tracking capability, viewing it as a medical device requiring regulatory clearance.
Whoop's blood pressure tool allows users to monitor cardiovascular health through its wrist-worn tracker. The feature had drawn FDA scrutiny over classification and approval pathways, leading to the agency's initial complaint.
The withdrawal suggests either a resolution between Whoop and the FDA regarding the tool's claims and functionality, or a reassessment by the agency of how consumer health tracking features should be regulated.
This outcome could have implications for other wearable manufacturers offering similar health monitoring capabilities. The fitness tracker market continues to expand its health-focused features, creating ongoing questions about where regulators draw lines between consumer wellness tools and medical devices.
Whoop has not yet publicly commented on the FDA's decision.
Rocket Lab founder Peter Beck said the company is pushing to launch its Neutron rocket for the first time this year. Beck told Bloomberg investors should look beyond the inaugural flight's significance.
TSMC and Sony have announced a joint venture called Advanced Vision Semiconductor Manufacturing Corp to produce next-generation smartphone image sensors in Japan starting in 2029.
A new project called Klepton enables Android ARM64 VR APKs to run natively on Apple Vision Pro, expanding the spatial computing device's app compatibility beyond Apple's ecosystem.